Interestingly, it has been reported that β2-agonists decrease the risk of Parkinson disease via epigenetic downregulation of SNCA gene transcription and protein reduction (68), and β2-adrenoreceptor signaling was previously described in podocytes (69). The gene discussed is SNCA; the disease is Parkinson disease.